A Study of Olanzapine in Patients With Acute Agitation

Clinical trial NCT05803642 · UNKNOWN

Trial details

NCT number: NCT05803642
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Agitation

Start date: 2023-03-28
Primary completion: 2024-05-07
Enrollment: 318

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.